Ropinirole prolonged release: in advanced Parkinson's disease.
Ropinirole prolonged release is a non-ergoline dopamine receptor agonist that is indicated for the treatment of Parkinson's disease. * Once-daily ropinirole prolonged release and three-times-daily ropinirole immediate release have similar exposure over 24 hours. The prolonged-release formulation is associated with fewer fluctuations in plasma ropinirole concentrations. * Two well designed, placebo- or active comparator-controlled trials examined the efficacy of ropinirole prolonged release in patients with advanced Parkinson's disease suboptimally controlled by levodopa. In the placebo-controlled trial, 24 weeks' therapy with ropinirole prolonged release 6-24 mg once daily reduced hours of 'off' time (primary endpoint) to a significantly greater extent than placebo. In the active comparator-controlled trial, significantly more ropinirole prolonged-release recipients than ropinirole immediate-release recipients maintained a >or=20% reduction from baseline in 'off' time at week 24 (primary endpoint). *Ropinirole prolonged release 6-24 mg once daily was generally well tolerated in patients with advanced Parkinson's disease; adverse events were generally typical of non-ergoline dopamine receptor agonists.
Weber
Juliane
J
Wolters Kluwer Health Adis, Auckland, New Zealand.
Keating
Gillian M
GM
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007211:Indoles; C046649:ropinirole